课题基金 / 基金详情

Study of a corticotropin releasing factor-1 receptor antagonist for the treatment of congenital adrenal hyperplasia

Study of a corticotropin releasing factor-1 receptor antagonist for the treatment of congenital adrenal hyperplasia
促肾上腺皮质激素释放因子1受体拮抗剂治疗先天性肾上腺皮质增生症的研究
批准号:
10266561
负责人:
Deborah Merke
金额:
$0.2万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Deborah Merke的其他基金

相关文献

中文摘要
翻译
在先天性肾上腺增生症中,经常需要过量的糖皮质激素治疗来控制肾上腺雄激素的过量产生。一项二期多中心临床试验正在进行中,该试验正在探索一种高亲和力和选择性的CRH 1型受体小分子拮抗剂在脑下垂体的剂量发现和疗效。该作用机制已在先前的概念验证研究中得到验证,并在健康志愿者的第一阶段临床研究中被证明是安全的。这项研究代表了一种治疗先天性肾上腺增生症的新疗法的早期研究。
英文摘要
Excess glucocorticoid therapy is often needed to control the overproduction of adrenal androgens in congenital adrenal hyperplasia. A phase 2 multicenter clinical trial is underway which is exploring dose finding as well as efficacy of a high-affinity and selective small-molecule antagonist of CRH type 1 receptors in the pituitary gland. The mechanism of action has been validated in a previous proof-of-concept study and has been shown to be safe in Phase 1 clinical studies in healthy volunteers. This study represents an early stage of the investigation of a novel therapy in the treatment of congenital adrenal hyperplasia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modified-release Hydrocortisone Therapy as a Treatment for CAH
Phase 2 Multi-center Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
  • 批准号:
    10252568
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Deborah Merke
  • 依托单位:
Novel treatment approaches: sex steroid blockade in children
  • 批准号:
    10916862
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Deborah Merke
  • 依托单位:
Study of a corticotropin releasing factor-1 receptor antagonist for the treatment of congenital adrenal hyperplasia
  • 批准号:
    10916863
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Deborah Merke
  • 依托单位: